Reich Kristian 4

What Happened
Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics (MLTX), reported a sale of 1,100 ordinary shares on July 27, 2026. The shares were disposed at $20.00 each for total proceeds of $22,000. The Form 4 indicates this was a sale (S) reported to the SEC.

Key Details

• Transaction date and price: July 27, 2026 — 1,100 shares sold at $20.00 per share (total $22,000).
• Method: Open market or private sale reported as "S" (sale).
• Plan/footnote: Executed pursuant to a pre-established Rule 10b5-1 trading plan adopted March 10, 2026 (Footnote F1).
• Indirect holdings: Footnote (F2) notes that JeruCON Beratungsgesellschaft mbH owns certain Issuer shares; Dr. Reich may be deemed an indirect beneficial owner of those shares.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.

Context

• Sales executed under a Rule 10b5-1 plan are typically pre-arranged, automated trading instructions and do not necessarily reflect the insider’s current view of the company.
• For retail investors, routine insider sales are less informative than purchases; this is a relatively small-dollar sale ($22k) by an executive and should be weighed alongside other insider activity and company fundamentals.